Skip to main content
Erschienen in: Journal of General Internal Medicine 8/2019

09.05.2019 | Review Article

Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials

verfasst von: Morten Rix Hansen, MD, PhD, Asbjørn Hróbjartsson, MD, PhD, Anton Pottegård, MScPharm, PhD, Per Damkier, MD, PhD, Kasper Søltoft Larsen, MD, PhD, Kenneth Grønkjær Madsen, MD, René dePont Christensen, M.Sc, PhD, Malene Elisa Lopez Kristensen, MScPharm, Palle Mark Christensen, MD, PhD, Jesper Hallas, MD, DMSc

Erschienen in: Journal of General Internal Medicine | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

The average postponement of the outcome (gain in time to event) has been proposed as a measure to convey the effect of preventive medications. Among its advantages over number needed to treat and relative risk reduction is a better intuitive understanding among lay persons.

Objectives

To develop a novel approach for modeling outcome postponement achieved within a trial’s duration, based on published trial data and to present a formalized meta-analysis of modeled outcome postponement for all-cause mortality in statin trials.

Methods

The outcome postponement was modeled on the basis of the hazard ratio or relative risk, the mortality rate in the placebo group and the trial’s duration. Outcome postponement was subjected to a meta-analysis. We also estimated the average outcome postponement as the area between Kaplan–Meier curves. Statin trials were identified through a systematic review.

Results

The median modeled outcome postponement was 10.0 days (interquartile range, 2.9–19.5 days). Meta-analysis of 16 trials provided a summary estimate of outcome postponement for all-cause mortality of 12.6 days, with a 95% postponement interval (PI) of 7.1–18.0. For primary, secondary, and mixed prevention trials, respectively, outcome postponements were 10.2 days (PI, 4.0–16.3), 17.4 days (PI, 6.0–28.8), and 8.5 days (PI, 1.9–15.0).

Conclusions

The modeled outcome postponement is amenable to meta-analysis and may be a useful approach for presenting the benefits of preventive interventions. Statin treatment results in a small increase of average survival within the duration of a trial.

Systematic Review Registration

The systematic review was registered in PROSPERO [CRD42016037507].
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy does the format of efficacy data determine patients’ acceptance of treatment? Med Decis Mak 1995;15(2):152–157.CrossRef Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy does the format of efficacy data determine patients’ acceptance of treatment? Med Decis Mak 1995;15(2):152–157.CrossRef
2.
Zurück zum Zitat Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med 1993;8(10):543–548.CrossRef Malenka DJ, Baron JA, Johansen S, Wahrenberger JW, Ross JM. The framing effect of relative and absolute risk. J Gen Intern Med 1993;8(10):543–548.CrossRef
4.
Zurück zum Zitat Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 1998;339(6):380–386.CrossRef Wright JC, Weinstein MC. Gains in life expectancy from medical interventions—standardizing data on outcomes. N Engl J Med 1998;339(6):380–386.CrossRef
6.
Zurück zum Zitat Christensen PM, Brosen K, Brixen K, Andersen M, Kristiansen IS. A randomized trial of laypersons’ perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. Clin Ther 2003;25(10):2575–2585.CrossRef Christensen PM, Brosen K, Brixen K, Andersen M, Kristiansen IS. A randomized trial of laypersons’ perception of the benefit of osteoporosis therapy: number needed to treat versus postponement of hip fracture. Clin Ther 2003;25(10):2575–2585.CrossRef
7.
Zurück zum Zitat Morris J, Hammitt JK. Using life expectancy to communicate benefits of health care programs in contingent valuation studies. Med Decis Mak 2001;21(6):468–478.CrossRef Morris J, Hammitt JK. Using life expectancy to communicate benefits of health care programs in contingent valuation studies. Med Decis Mak 2001;21(6):468–478.CrossRef
9.
Zurück zum Zitat Kapur NK, Musunuru K, et al. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008;4(2):341.CrossRef Kapur NK, Musunuru K, et al. Clinical efficacy and safety of statins in managing cardiovascular risk. Vasc Health Risk Manag 2008;4(2):341.CrossRef
10.
Zurück zum Zitat Trialists CT, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670–1681.CrossRef Trialists CT, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010;376(9753):1670–1681.CrossRef
11.
Zurück zum Zitat Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Vol 2008. Higgins JPT, Green S. Cochrane Handbook for Systematic Reviews of Interventions. Vol 2008.
12.
Zurück zum Zitat Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149–1158. https://doi.org/10.1016/S0140-6736(03)12948-0 CrossRefPubMed Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003;361(9364):1149–1158. https://​doi.​org/​10.​1016/​S0140-6736(03)12948-0 CrossRefPubMed
14.
Zurück zum Zitat Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195.CrossRef Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359(21):2195.CrossRef
15.
Zurück zum Zitat Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333(20):1301–1308.CrossRef Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333(20):1301–1308.CrossRef
16.
Zurück zum Zitat Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383–1389.
18.
Zurück zum Zitat Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349–1357. doi:https://doi.org/10.1056/NEJM199811053391902 Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998;339(19):1349–1357. doi:https://​doi.​org/​10.​1056/​NEJM199811053391​902
19.
Zurück zum Zitat Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248–2261.CrossRef Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007;357(22):2248–2261.CrossRef
21.
Zurück zum Zitat Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024–2031.CrossRef Holdaas H, Fellström B, Jardine AG, et al. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003;361(9374):2024–2031.CrossRef
25.
Zurück zum Zitat Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA J Am Med Assoc 2002;287(24):3215–3222.CrossRef Serruys PWJC, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. JAMA J Am Med Assoc 2002;287(24):3215–3222.CrossRef
26.
Zurück zum Zitat Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–1630.CrossRef Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623–1630.CrossRef
28.
Zurück zum Zitat Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017:j4530. doi:https://doi.org/10.1136/bmj.j4530 Davis C, Naci H, Gurpinar E, Poplavska E, Pinto A, Aggarwal A. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017:j4530. doi:https://​doi.​org/​10.​1136/​bmj.​j4530
29.
Zurück zum Zitat Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med 2007;146(12):848–856.CrossRef Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. Ann Intern Med 2007;146(12):848–856.CrossRef
30.
Zurück zum Zitat Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials, an analysis of end point postponement, Web comments. BMJ Open 2015;5(9):e007118.CrossRef Kristensen ML, Christensen PM, Hallas J. The effect of statins on average survival in randomised trials, an analysis of end point postponement, Web comments. BMJ Open 2015;5(9):e007118.CrossRef
34.
Zurück zum Zitat Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010;48(3):196–202.CrossRef Chan DC, Shrank WH, Cutler D, et al. Patient, physician, and payment predictors of statin adherence. Med Care 2010;48(3):196–202.CrossRef
35.
Zurück zum Zitat Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073–1080.CrossRef Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy 20-year follow-up of West of Scotland Coronary Prevention Study. Circulation. 2016;133(11):1073–1080.CrossRef
37.
38.
Zurück zum Zitat Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013;13(1):152.CrossRef Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol 2013;13(1):152.CrossRef
39.
Zurück zum Zitat Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781–1790.CrossRef Armitage J. The safety of statins in clinical practice. Lancet 2007;370(9601):1781–1790.CrossRef
40.
Zurück zum Zitat Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336(5):332–336.CrossRef Johannesson M, Jönsson B, Kjekshus J, Olsson AG, Pedersen TR, Wedel H. Cost effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease. N Engl J Med 1997;336(5):332–336.CrossRef
Metadaten
Titel
Postponement of Death by Statin Use: a Systematic Review and Meta-analysis of Randomized Clinical Trials
verfasst von
Morten Rix Hansen, MD, PhD
Asbjørn Hróbjartsson, MD, PhD
Anton Pottegård, MScPharm, PhD
Per Damkier, MD, PhD
Kasper Søltoft Larsen, MD, PhD
Kenneth Grønkjær Madsen, MD
René dePont Christensen, M.Sc, PhD
Malene Elisa Lopez Kristensen, MScPharm
Palle Mark Christensen, MD, PhD
Jesper Hallas, MD, DMSc
Publikationsdatum
09.05.2019
Verlag
Springer US
Erschienen in
Journal of General Internal Medicine / Ausgabe 8/2019
Print ISSN: 0884-8734
Elektronische ISSN: 1525-1497
DOI
https://doi.org/10.1007/s11606-019-05024-4

Weitere Artikel der Ausgabe 8/2019

Journal of General Internal Medicine 8/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.